OBJECTIVE: In ankylosing spondylitis (AS), tumor necrosis factor (TNF) blockers are recommended for patients with high symptomatic disease activity. Few data are available about objective signs of inflammation such as increased C-reactive protein (CRP). We assessed the retention rate of TNF blockers in patients with axial AS, according to baseline CRP and other potentially predictive measures. METHODS: A retrospective study of all patients treated with TNF blockers for axial AS. Retention rate was evaluated using a survival-data analysis technique with discontinuation of the drug because of inefficacy (Kaplan-Meier method). Potential factors explaining the retention rates (demographic and clinical indicators and CRP) were evaluated using log-rank tests and a Cox proportional-hazards regression model. RESULTS: For axial AS, 175 patients received TNF blockers (men 78%, mean disease duration 12.4 +/- 9.1 yrs); 100 patients (of 143 with available data) had an increased CRP (> 10 mg/l). An increased CRP at baseline was the only variable explaining the retention rate in the Cox model (p = 0.003, hazard ratio = 3.3, 95% CI 1.5-7.3). CONCLUSION: Interruption for expert opinion of inefficacy was more frequent for patients with low baseline CRP; however, even in these patients retention was high. Increased CRP should not be considered mandatory for proposing TNF blocker treatment in axial AS.
OBJECTIVE: In ankylosing spondylitis (AS), tumor necrosis factor (TNF) blockers are recommended for patients with high symptomatic disease activity. Few data are available about objective signs of inflammation such as increased C-reactive protein (CRP). We assessed the retention rate of TNF blockers in patients with axial AS, according to baseline CRP and other potentially predictive measures. METHODS: A retrospective study of all patients treated with TNF blockers for axial AS. Retention rate was evaluated using a survival-data analysis technique with discontinuation of the drug because of inefficacy (Kaplan-Meier method). Potential factors explaining the retention rates (demographic and clinical indicators and CRP) were evaluated using log-rank tests and a Cox proportional-hazards regression model. RESULTS: For axial AS, 175 patients received TNF blockers (men 78%, mean disease duration 12.4 +/- 9.1 yrs); 100 patients (of 143 with available data) had an increased CRP (> 10 mg/l). An increased CRP at baseline was the only variable explaining the retention rate in the Cox model (p = 0.003, hazard ratio = 3.3, 95% CI 1.5-7.3). CONCLUSION: Interruption for expert opinion of inefficacy was more frequent for patients with low baseline CRP; however, even in these patients retention was high. Increased CRP should not be considered mandatory for proposing TNF blocker treatment in axial AS.
Authors: Yuen Ling Elaine Au; Woon Sing Raymond Wong; Mo Yin Mok; Ho Yin Chung; Eric Chan; Chak Sing Lau Journal: Clin Rheumatol Date: 2014-07-01 Impact factor: 2.980
Authors: M Fabris; L Quartuccio; C Fabro; S Sacco; S Lombardi; R Ramonda; D Biasi; D Punzi; S Adami; I Olivieri; F Curcio; S De Vita Journal: Pharmacogenomics J Date: 2015-07-07 Impact factor: 3.550
Authors: Pascal Zufferey; Jacqueline Ghosn; Fabio Becce; Adrian Ciurea; Bérengère Aubry-Rozier; Axel Finckh; Alexander K So Journal: Rheumatol Int Date: 2014-07-29 Impact factor: 2.631
Authors: Ursula Schulte-Wrede; Till Sörensen; Joachim R Grün; Thomas Häupl; Heike Hirseland; Marta Steinbrich-Zöllner; Peihua Wu; Andreas Radbruch; Denis Poddubnyy; Joachim Sieper; Uta Syrbe; Andreas Grützkau Journal: Arthritis Res Ther Date: 2018-08-29 Impact factor: 5.156
Authors: Johan K Wallman; Meliha C Kapetanovic; Ingemar F Petersson; Pierre Geborek; Lars Erik Kristensen Journal: Arthritis Res Ther Date: 2015-12-24 Impact factor: 5.156